GHK-Cu

GHK-Cu is a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper (II) ions. The peptide was first identified in human plasma in 1973 by researcher Loren Pickart, who discovered that it had a profound stimulating effect on liver tissue repair. Since then, GHK has been found in multiple biological fluids, including saliva, urine, and wound fluid, and functions as a tissue remodeling signal throughout the body. Notably, plasma concentrations of GHK decline sharply with age: from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60.

The mechanisms behind GHK-Cu are unusually broad. At the extracellular matrix level, the peptide simultaneously stimulates synthesis of collagen, glycosaminoglycans, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin, while also upregulating metalloproteinase activity to degrade and remove damaged collagen. This dual stimulation-and-cleanup action accelerates tissue remodeling. GHK-Cu also promotes angiogenesis, exerts anticoagulant and vasodilatory effects, and exhibits potent anti-inflammatory activity by reducing key cytokines such as IL-6. Large-scale gene expression analyses have identified over 4,000 human genes modulated by GHK, including genes involved in DNA repair, mitochondrial function, and the suppression of cancer-associated pathways.

Clinical and human research on GHK-Cu spans both wound healing and cosmetic applications. In wound healing studies, collagen dressings incorporating GHK accelerated healing in healthy and diabetic rat models, with treated wounds showing 9-fold higher collagen content. In a human cosmetic trial, female volunteers applying GHK-Cu encapsulated in nano-lipid carriers twice daily for 8 weeks showed a 31.6% reduction in wrinkle volume compared to a Matrixyl 3000 control group.

GHK-Cu occupies an unusual position in the peptide landscape: it has decades of safety data in cosmetic formulations (where it is used at concentrations up to 0.002%), a well-documented mechanism of action at nanomolar concentrations, and plausible systemic benefits from injectable forms. It remains unapproved by the FDA for any therapeutic indication but is widely used in cosmetic products under established safety parameters.